Turner Danielle
University of Cambridge, Department of Psychiatry, Box 189, Addenbrooke's Hospital, Cambridge, CB2 2QQ UK.
Expert Rev Neurother. 2006 Apr;6(4):455-68. doi: 10.1586/14737175.6.4.455.
Modafinil (Provigil) is a novel wakefulness-promoting agent that has been shown to have greater efficacy than placebo in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. In particular, three large, drug-company sponsored trials of a film-coated formulation of modafinil (modafinil-ADHD; Sparlon) in children and adolescents with ADHD demonstrated consistent improvements in ADHD symptoms compared with placebo. Mean reductions in symptom ratings (measured using the ADHD-Rating Scale-IV school version questionnaire) ranged from 15.0 to 19.7 (7.3 to 10.1 for placebo). The most common adverse events were insomnia, headache and decreased appetite. Modafinil was generally well tolerated with most side effects considered mild to moderate in severity. Modafinil may have advantages over current therapies for ADHD in that it can be administered once daily and has fewer reinforcing properties than traditional stimulants. Modafinil could potentially be a valuable new treatment option for patients with ADHD. However, rigorous comparative studies with current first-line treatments for ADHD and longer-term independent studies are necessary before modafinil's role in the treatment of ADHD can be fully established.
莫达非尼（普罗维吉尔）是一种新型促醒药物，已证明在治疗儿童和成人注意力缺陷多动障碍（ADHD）方面比安慰剂更有效。特别是，三项由制药公司赞助的针对患有ADHD的儿童和青少年的莫达非尼薄膜包衣制剂（莫达非尼 - ADHD；斯帕隆）的大型试验表明，与安慰剂相比，ADHD症状有持续改善。症状评分的平均降低幅度（使用ADHD评定量表-IV学校版问卷测量）为15.0至19.7（安慰剂为7.3至10.1）。最常见的不良事件是失眠、头痛和食欲减退。莫达非尼总体耐受性良好，大多数副作用的严重程度被认为是轻度至中度。莫达非尼相对于目前治疗ADHD的疗法可能具有优势，因为它可以每日服用一次，并且与传统兴奋剂相比，强化特性较少。莫达非尼可能是ADHD患者一种有价值的新治疗选择。然而，在莫达非尼在ADHD治疗中的作用得以完全确立之前，有必要与目前治疗ADHD的一线疗法进行严格的比较研究以及开展长期的独立研究。
